AR040200A1 - Antagonistas novedosos de quimiocinas cxc de union con cxcr3 - Google Patents

Antagonistas novedosos de quimiocinas cxc de union con cxcr3

Info

Publication number
AR040200A1
AR040200A1 ARP030102092A ARP030102092A AR040200A1 AR 040200 A1 AR040200 A1 AR 040200A1 AR P030102092 A ARP030102092 A AR P030102092A AR P030102092 A ARP030102092 A AR P030102092A AR 040200 A1 AR040200 A1 AR 040200A1
Authority
AR
Argentina
Prior art keywords
cxcr3
binding
cxc
antagonists
diseases
Prior art date
Application number
ARP030102092A
Other languages
English (en)
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of AR040200A1 publication Critical patent/AR040200A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)

Abstract

Antagonistas novedosos de quimiocinas CXC de unión con CXCR3, y en particular de CXCL11 humana, pueden obtenerse generando mutantes de dichas quimiocinas en donde la unión a glicosaminoglicanos (GAGs) es perjudicada debido a las sustituciones no conservadoras de aminoácidos que participan en esta interacción. Los compuestos preparados de acuerdo con la presente pueden utilizarse para bloquear la actividad de quimiocinas CXC de unión con CXCR3 sobre células que expresan CXCR3, suministrando de ese modo composiciones terapéuticas para uso en el tratamiento o prevención de enfermedades relacionadas con una excesiva migración de células T activadas, tal como enfermedades por rechazo de injertos y autoinmunes, y de enfermedades que necesitan un aumento de vascularización, tal como enfermedad cardiaca isquémica. Reivindicación 1: Antagonistas de quimiocinas CXC de unión con CXCR3 que comprenden mutantes de CXCL11, CXCL10, o CXCL9 en donde por lo menos uno de los siguientes residuos básicos, numerados en la secuencia de CXCL11 madura humana, es sustituido en Alanina, Glicina, Serina, Treonina, Prolina, Ácido Glutámico, Glutamina, Ácido Aspártico o Asparagina: 46, 62, 66, y 70.
ARP030102092A 2002-06-12 2003-06-11 Antagonistas novedosos de quimiocinas cxc de union con cxcr3 AR040200A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02100697 2002-06-12

Publications (1)

Publication Number Publication Date
AR040200A1 true AR040200A1 (es) 2005-03-16

Family

ID=29724537

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030102092A AR040200A1 (es) 2002-06-12 2003-06-11 Antagonistas novedosos de quimiocinas cxc de union con cxcr3

Country Status (16)

Country Link
US (1) US7541435B2 (es)
EP (1) EP1515990B1 (es)
JP (1) JP4394569B2 (es)
AR (1) AR040200A1 (es)
AT (1) ATE359297T1 (es)
AU (1) AU2003255505B2 (es)
CA (1) CA2489298C (es)
CY (1) CY1106799T1 (es)
DE (1) DE60313168T2 (es)
DK (1) DK1515990T3 (es)
ES (1) ES2282666T3 (es)
IL (1) IL165727A (es)
NO (1) NO332309B1 (es)
PT (1) PT1515990E (es)
SI (1) SI1515990T1 (es)
WO (1) WO2003106488A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7964194B2 (en) * 2002-11-15 2011-06-21 Morehouse School Of Medicine Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation
CA2558813A1 (en) * 2004-03-09 2005-09-15 Kyoto University Pharmaceutical composition comprising cxcr3 inhibitor
ITFI20040243A1 (it) * 2004-11-25 2005-02-25 Paola Romagnani Metodo diagnostico per la previsione di rigetto di organo trapiantato
WO2006069449A1 (en) * 2004-12-29 2006-07-06 The University Of British Columbia Chemokine receptor-independent immunomodulatory and anti-proliferative activity
US20090131312A1 (en) * 2005-05-18 2009-05-21 Lawrence Blatt Non-natural chemokine receptor ligands and methods of use thereof
CN101678082B (zh) 2007-03-26 2013-06-19 再生医药有限公司 使用cxcl9和抗cxcl9抗体促进骨髓保护和再生的方法
ES2456963T3 (es) * 2007-06-04 2014-04-24 Rappaport Family Institute For Research In The Medical Sciences Agentes para el tratamiento de enfermedades inflamatorias y métodos para usar los mismos
WO2010129351A1 (en) 2009-04-28 2010-11-11 Schepens Eye Research Institute Method to identify and treat age-related macular degeneration
US10983128B2 (en) 2015-02-05 2021-04-20 Bristol-Myers Squibb Company CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy
EP3288587A4 (en) * 2015-04-29 2018-09-12 Sanford-Burnham Medical Research Institute Modulation of immune response using btla agonist antibodies
WO2018106959A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
WO2018112264A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
WO2020106757A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
US11707610B2 (en) 2019-12-13 2023-07-25 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
GB202214951D0 (en) * 2022-10-11 2022-11-23 Univ London Queen Mary CXC receptor ligands

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739103A (en) * 1993-11-12 1998-04-14 Dana-Farber Cancer Institute Chemokine N-terminal deletion mutations
US5656724A (en) 1994-10-26 1997-08-12 Repligen Corporation Chemokine-like proteins and methods of use
US5707829A (en) 1995-08-11 1998-01-13 Genetics Institute, Inc. DNA sequences and secreted proteins encoded thereby
US6140064A (en) * 1996-09-10 2000-10-31 Theodor-Kocher Institute Method of detecting or identifying ligands, inhibitors or promoters of CXC chemokine receptor 3
US5977334A (en) 1997-09-11 1999-11-02 The Cleveland Clinic Foundation DNA encoding a chemokine, Beta R1, comprising the Beta R1 promoter
US20020018776A1 (en) * 2000-04-14 2002-02-14 Millennium Pharmaceuticals, Inc. Method of treating graft rejection using inhibitors of CXCR3 function
BR0112428A (pt) * 2000-07-12 2003-11-25 Gryphon Therapeutics Inc Quimiocinas sintéticas boativas modificadas por polìmero e métodos para sua produção e uso
JP2004517078A (ja) 2000-12-01 2004-06-10 シェーリング　コーポレイション 哺乳動物遺伝子および関連試薬の使用

Also Published As

Publication number Publication date
PT1515990E (pt) 2007-05-31
SI1515990T1 (sl) 2007-08-31
AU2003255505A1 (en) 2003-12-31
EP1515990B1 (en) 2007-04-11
NO332309B1 (no) 2012-08-20
WO2003106488A2 (en) 2003-12-24
DE60313168D1 (de) 2007-05-24
NO20050162L (no) 2005-01-12
DE60313168T2 (de) 2007-12-20
ES2282666T3 (es) 2007-10-16
WO2003106488A3 (en) 2004-04-15
JP4394569B2 (ja) 2010-01-06
CY1106799T1 (el) 2012-10-24
IL165727A (en) 2010-05-17
EP1515990A2 (en) 2005-03-23
CA2489298A1 (en) 2003-12-24
IL165727A0 (en) 2006-01-15
JP2006511200A (ja) 2006-04-06
US7541435B2 (en) 2009-06-02
US20060204498A1 (en) 2006-09-14
DK1515990T3 (da) 2007-06-11
AU2003255505B2 (en) 2009-01-08
ATE359297T1 (de) 2007-05-15
CA2489298C (en) 2012-09-11

Similar Documents

Publication Publication Date Title
AR040200A1 (es) Antagonistas novedosos de quimiocinas cxc de union con cxcr3
AR008444A1 (es) Empleo de antagonistas de leptina para el tratamiento de la resistencia a la insulina en diabetes del tipo ii
CR11042A (es) Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes
AR036711A1 (es) Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
AR039629A1 (es) Antagonistas de proteinas mcp
CR8793A (es) Piridinas sustituidas y su uso como farmaceuticos
PE20061115A1 (es) Anticuerpos anti-il-12, epitopos, composiciones, metodos y usos
DK1131065T3 (da) Diakyldumarater til behandling af autoimmunsygdomme
MX9205985A (es) Epitopes de las celulas t de los alergenos principales del genero dermatophagoides y composiciones farmaceuticas que los contienen.
UY27595A1 (es) Compuestos de succinimida heterocíclicos, fusionados y analógos de los mismos, moduladores de la función del receptor de la hormona nuclear
PE20080339A1 (es) Polipeptidos del factor de coagulacion ix modificados y uso de los mismos para tratamiento
CR8702A (es) Compuestos amido y sus usos como farmaceuticos
ES2157027T3 (es) Oxazolidinonas sustituidas y su uso como farmacos antibacterianos.
ES2123810T3 (es) Heterociclos utiles como antagonistas de neuroquinina.
CR8901A (es) Compuestos de amido y sus usos como farmaceuticos
AR010065A1 (es) COMPUESTOS HETEROCíCLICOS Y EL USO DE LOS MISMOS PARA LA PREPARACION DE FARMACOS UTILES COMO INHIBIDORES DE LA ADHESION DE LEUCOCITOS Y ANTAGONISTAS DE LA VLA-4
GT200500260A (es) Amidas biciclicas como inhibidores de cinasa.
EA200000379A1 (ru) Усеченные по амино-концу rantes как антагонисты хемокинов
HRP20220068T1 (hr) Staphylococcus aureus leukocidini, terapijski pripravci, i njihova uporaba
ES2061019T3 (es) Vendaje elastico tejido o de punto.
ES2125618T3 (es) Alfa b cristalina para uso en el diagnostico y el tratamiento de enfermedades auto-inmunes y en particular la esclerosis multiple.
MX9401172A (es) Derivados fluorados de 4-aminoandrostadienona, procesamiento para su preparacion y composiciones farmaceuticas que los contienen.
ES2083636T3 (es) Componente adhesivo para la restauracion de la sustancia dental dura.
NO20062316L (no) Nye CXCL8 antagonister
AR114291A1 (es) Conjugados de péptido tirosina tirosina cíclico con péptido de fusión del péptido similar al glucagón tipo 1 (glp-1) acoplado y usos de estos

Legal Events

Date Code Title Description
FG Grant, registration